The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Can we target AML with CAR T-cells?
CAR T-cells are the most exciting type of therapy in the hematology world. They have been used in a variety of diseases and demonstrated to have deep responses, lasting up to 1 year. The most common targets are CD19 and BCMA; however, acute myeloid leukemia (AML) cells do not express these targets, which difficults the use of existing CAR T-cells constructs. Here, Attilio Bondanza, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about the work himself and his colleagues have been doing on CAR T-cells that target CD44 isoform variant 6 (CD44v6), which is over-expressed in AML, and that was presented at the European Hematology Association (EHA) 2017 meeting.
